medRxiv preprint doi: https://doi.org/10.1101/2020.02.18.20024539; this version posted February 23, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

Clinical characteristics of 50404 patients with 2019-nCoV infection

Pengfei Sun[1],Shuyan Qie[2],Zongjan Liu[2], Jizhen Ren[3],Jianing Xi[4]

[1]Department of Plastic Surgery, Zibo Central Hospital, 255000, Zibo, China

[2]Department of Rehabilitation, Beijing Rehabilitation Hospital of Capital Medical University, 100044,Beijing, China

[3]Department of Plastic Surgery, Affiliated Hospital of Qingdao University, 266000 ,Qingdao, China

[4]Department of Respiratory Rehabilitation, Beijing Rehabilitation Hospital of Capital Medical University, 100044,Beijing, China

Corresponding author

Abstract

Objective: To provide reliable evidence of evidence-based medicine for the treatment and prevention of the 2019 novel coronavirus(2019-nCoV) by analyzing all the published studies on the clinical characteristics of patients with 2019-nCoV.

Methods: PubMed,Cochrane Library,Embase and other databases were searched. Some studies on the clinical characteristics of 2019-nCoV infection were collected for Meta-analysis

.Results: 9 studies were included in Meta-analysis, including a total of 50404 patients with 2019-nCoV infection.According to Meta-analysis, among the clinical characteristics of patients with 2019-nCoV infection, the incidence of fever is 90.9% , the incidence of cough is 70.8%, and the incidence of muscle soreness or fatigue is 41%. The incidence of acute respiratory distress syndrome (ARDS) was 14.8%, the incidence of abnormal chest CT was 95.6%, the proportion of severe cases in all infected cases was 21.3%, and the mortality rate of patients with 2019-nCoV infection was 4.8%.

Conclusion: Fever and cough are the most common symptoms in patients with 2019-nCoV infection, and most of them have abnormal chest CT examination.Some people have muscle soreness or fatigue, ARDS. Diarrhea, hemoptysis, headache, sore throat, shock and other symptoms only occur in a small number of patients.The mortality rate of patients with 2019-nCoV infection was lower than that of Severe Acute Respiratory Syndrome (SRAS) and Middle East Respiratory Syndrome (MERS).

Highlights

medRxiv preprint doi: https://doi.org/10.1101/2020.02.18.20024539; this version posted February 23, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

A total of 9 articles were included in the Meta-analysis, including 50404 patients with 2019-nCoV infection, which was the first Meta-analysis with the largest sample size.The quality of the literature included in this study was high, the analysis was rigorous, and the conclusions drawn by the study were highly credible.

Keywords 2019-nCoV, Coronavirus, Meta-analysis, Mortality, Clinical Symptoms

Abbreviations

WHO=the World Health Organization

2019-nCoV=the 2019 novel coronavirus

SRAS=Severe Acute Respiratory Syndrome

ARDS=Acute Respiratory Distress Syndrome

NOS=the Newcastle-Ottawa Scale

MERS=Middle East Respiratory Syndrome

ACE2=Angiotensin Converting Enzyme 2

TGF-β=Transforming Growth Factor-β

medRxiv preprint doi: https://doi.org/10.1101/2020.02.18.20024539; this version posted February 23, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

China CDC=Chinese Center for Disease Control and Prevention

1 Introduction

Since December 2019, a series of unexplained cases of infectious pneumonia have occurred in Wuhan, China. The Chinese government and researchers have taken rapid measures to control the epidemic [1].On January 12, 2020, the World Health Organization (WHO) provisionally named the 2019 novel coronavirus(2019-nCoV).On January 30, 2020, WHO announced that the 2019-nCoV outbreak was a public health emergency of international concern.At present, the number of patients with 2019-nCoV infection is still rising, and its harm to human beings has exceeded the outbreak of Severe Acute Respiratory Syndrome (SRAS) in China in 2002 [2].The clinical characteristics and mortality after 2019-nCoV infection have always been concerned by people, and it is also the focus of medical workers' research at present.However, due to the different design of different clinical studies and insufficient sample size, the conclusions of the published studies are different.In order to get more accurate conclusions

medRxiv preprint doi: https://doi.org/10.1101/2020.02.18.20024539; this version posted February 23, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

about the clinical characteristics and mortality of patients with 2019-nCoV infection, we searched the relevant papers for single arm Meta-analysis.We hope that our findings will provide guidance for current clinical work on the prevention and treatment of 2019-nCoV infection.

2 Material and Methods

2.1 Search strategy

Relevant papers from PubMed, Cochrane Library, and Embase databases were extracted by us. Articles reviewed were dated up to February 2020. Keywords retrieved were "2019-nCoV", "Coronavirus" and "Wuhan Coronavirus". In this Meta-analysis, there was no language restriction, only the available data from published articles were extracted, and the unpublished papers were not included.

2.2 The inclusive criteria and exclusive criteria

2.2.1 Inclusive criteria:the study was designed for randomized controlled trials, non-randomized controlled trials, case-control studies, cohort studies, cross-sectional studies, case reports, etc., on the clinical characteristics of patients with 2019-nCoV infection.The clinical characteristics of patients with 2019-nCoV infection include fever, cough, muscle soreness or fatigue, acute respiratory distress syndrome(ARDS), abnormal chest CT detection, patients in critical condition, death due to 2019-nCoV infection and so on.

medRxiv preprint doi: https://doi.org/10.1101/2020.02.18.20024539; this version posted February 23, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.

2.2.2 Exclusive criteria:the articles were published repeatedly; the studies did not include the research indicators needed for Meta-analysis; the research data were missing.

2.3 Data extraction and paper quality evaluation

First of all, the researchers screened the literature according to the literature abstract, excluded the articles that obviously did not meet the inclusion criteria, and then read the full text for re-screening.If there is a disagreement on the choice of the literature, it shall be decided by the intervention of the third evaluator or the discussion between the two researchers.The included literature quality was evaluated using the Newcastle-Ottawa Scale (NOS) [4]. The highest quality of the literature is 9 stars and the lowest is 0 stars.

2.4 Statistical analysis

We used the statistical software Stata version 12.0 to carry out the single arm Meta-analysis.The original data included in the literature are first transformed by double arcsine method to make them conform to normal distribution and then analyzed by software.The conclusion obtained by Meta-analysis is then restored by using formula ($P=(\sin(tp/2))^2$) to get the final conclusion.In order to objectively evaluate the publication bias of the included literature, we used the Egger test to test the publication bias, and set $P < 0.05$ as the existence of publication bias, on the contrary, there is no publication bias.

medRxiv preprint doi: https://doi.org/10.1101/2020.02.18.20024539; this version posted February 23, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.

3 Results

3.1 Literature inclusion

A total of 283 articles were retrieved, 39 papers were eliminated due to repeated retrieval, and 212 papers were deleted after reading abstracts that did not meet the inclusion criteria. After reading the full text, 23 papers were eliminated because they did not meet the inclusion criteria or were unable to extract useful data.In the end, a total of 9 articles [5-13] were included in this Meta-analysis, including 50404 patients.The specific operation flow is shown in Figure 1.The characteristics of the literature are shown in Table 1.

3.2 Meta-analysis results

Through the Meta-analysis, we found that in the clinical characteristics of patients with 2019-nCoV infection, the incidence of fever is 90.9% (Figure 2), the incidence of cough is 70.8% (Figure 3), and the incidence of muscle soreness or fatigue is 41% (Figure 4). The incidence of ARDS was 14.8% (Figure 5), the incidence of abnormal chest CT was 95.6% (Figure 6), the proportion of severe cases in all infected cases was 21.3% (Figure 7), and the mortality rate of patients with 2019-nCoV infection was 4.8% (Figure 8).The detailed results of Meta-analysis are shown in Table 2.

3.3 Publication bias detection

medRxiv preprint doi: https://doi.org/10.1101/2020.02.18.20024539; this version posted February 23, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.

The results of Egger test in Table 3. There was publication bias in the analysis of the ARDS group(P=0.008).

4 Discussion

2019-nCoV is a kind of coronavirus and belongs to β-coronavirus cluster.It is the third kind of zoonotic coronavirus disease after SARS and Middle East Respiratory Syndrome (MERS).Wei Ji et al. [14] found that 2019-nCoV seems to be a recombinant virus between bat coronavirus and coronavirus of unknown origin.By comparing with other animals, it was confirmed that snakes were the most likely wildlife repositories for 2019-nCoV.The research of Domenico Benvenuto et al. [15] showed that 2019-nCoV was only closely related to the coronavirus isolated from Chinese chrysanthemum-headed bat in 2015.Their research supported the hypothesis that the transmission chain begins in bats and reaches humans.According to the research of Peng Zhou et al. [16] and Fan Wu et al. [17], it was found that the sequence homology between 2019-nCoV and SARS-CoV was 79.5%.The homology between 2019-nCoV and bat coronavirus at the genetic level was 96%.Therefore, we can basically confirm that 2019-nCoV comes from bats.

According to the results of Meta-analysis, we can find that the most common symptoms of patients with 2019-nCoV infection were fever and cough, and most of the patients had abnormal chest CT.Some patients with 2019-nCoV infection will have muscle soreness or fatigue, ARDS and other symptoms.Diarrhea, hemoptysis, headache, sore throat, shock and other symptoms only occured in a small number of patients. The proportion of

medRxiv preprint doi: https://doi.org/10.1101/2020.02.18.20024539; this version posted February 23, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.

severe cases in all infected cases was 21.3%, and the mortality rate was 4.8%.At present, the Chinese government has announced that the mortality rate of patients with 2019-nCoV infection in China is 2.4%.Therefore, the mortality rate of patients with 2019-nCoV infection is lower than that of the other two widely contagious zoonotic coronavirus diseases, SARS and MERS, whose infection mortality rates are 9.6% [18] and 35% [19], respectively.

Gaohong Sheng et al. [20] have shown that viral infection can increase the risk of pulmonary fibrosis.Xie et al. [21] found that 45% of patients showed signs of pulmonary fibrosis within one month after being infected with SARS-CoV.Hui et al. [22] found that 36% and 30% of patients infected with SARS-CoV developed pulmonary fibrosis at 3 and 6 months after infection, respectively.Therefore, we believe that pulmonary fibrosis will become one of the serious complications in patients with 2019-nCoV infection.How to prevent and reduce the occurrence of pulmonary fibrosis in patients with 2019-nCoV infection is an urgent problem for medical workers in the treatment of 2019-nCoV.

Yu Zhao et al. [23] found that angiotensin converting enzyme 2 (ACE2) is the receptor of 2019-nCoV.In normal lung tissue, ACE2 is mainly expressed by type □ and type □ alveolar epithelial cells.Among them, 83% of II-type alveolar cells expressed ACE2.2019-nCoV binds to ACE2 and ACE2 is highly expressed in II type alveolar cells resulting in alveolar cell injury.In addition, the use of mechanical ventilation in the treatment of patients with 2019-nCoV infection can also aggravate the injury of alveolar cells.After alveolar cell injury, the release of transforming growth

medRxiv preprint doi: https://doi.org/10.1101/2020.02.18.20024539; this version posted February 23, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.

factor-β (TGF- β) in tissue promotes lung repair. Virus infection often leads to excessive activation of TGF- β pathway, which leads to the occurrence of pulmonary fibrosis.

According to the mechanism of pulmonary fibrosis after virus infection, we can formulate corresponding prevention and treatment measures.The first is the treatment of 2019-nCoV infection. At present, a variety of drugs have been found to inhibit 2019-nCoV.Michelle L. Holshue et al. [24] have also achieved remarkable results in the treatment of patients with 2019-nCoV infection with remdesivir, and the drug was currently in clinical trials.Second, it is necessary to inhibit the inflammatory reaction and reduce the exudation.Antibiotics not only have traditional antibacterial effects, but also have immunomodulatory and anti-inflammatory properties [25].Macrolide antibiotics such as clarithromycin, azithromycin and erythromycin can prevent the production of proinflammatory cytokines and immune mediators [26].The third is to inhibit the fibrogenic effect of TGF- β.Luo et al. [27] found that arsenic trioxide can inhibit the signal transduction of TGF- β and play a role in anti-fibrosis.The fourth is the rational use of ventilator, less lung injury in patients.In addition, pirfenidone and nintedanib as drugs for the treatment of idiopathic pulmonary fibrosis can also be used to prevent and treat pulmonary fibrosis in patients with 2019-nCoV infection [28].

A total of 9 articles were included in the Meta-analysis, including 50404 patients with 2019-nCoV infection, which was the first Meta-analysis with the largest sample size.The quality of the literature included in this study was high, the analysis was rigorous, and the conclusions drawn by the study

medRxiv preprint doi: https://doi.org/10.1101/2020.02.18.20024539; this version posted February 23, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.

were highly credible. However, this Meta-analysis also has some limitations: 1. All the studies included in this Meta-analysis were retrospective studies with large heterogeneity. 2. Most of the patients in our Meta-analysis were Chinese, and we use the conclusions of this study to predict that patients from other countries and races have limitations; 3. There was publication bias in the analysis of the ARDS group. The analytical conclusions of the ARDS group may be influenced by publication bias.

Due to the above limitations, the conclusions of this Meta-analysis still need to be verified by more relevant studies with reasonable design, rigorous execution and large sample size.

Declaration of interests: The authors have declared that there is no conflict of interest in this study.

Acknowledgements: Noting.

medRxiv preprint doi: https://doi.org/10.1101/2020.02.18.20024539; this version posted February 23, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

References

[1] Lancet T, 2020. Emerging understandings of 2019-nCoV. Lancet. 395(10221): 311.

[2] Lu H, Stratton CW, Tang YW. Outbreak of Pneumonia of Unknown Etiology in Wuhan China: the Mystery and the Miracle. J Med Virol 2020. doi: 10.1002/jmv.25678.

[3] Moher D, Liberati A, Tetzlaff J, Altman DG; PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. J Clin Epidemiol 2009. 62(10):1006-1012.

[4] Stang A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses.Eur J Epidemiol 2010. 25(9):603-605.

[5] Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 2020. pii: S0140-6736(20)30183-5.

[6] Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, et al. Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. JAMA 2020. doi: 10.1001/jama.2020.1585.

medRxiv preprint doi: https://doi.org/10.1101/2020.02.18.20024539; this version posted February 23, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

[7] Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet 2020. pii: S0140-6736(20)30211-7.

[8] Weijie Guan, Zhengyi Ni, Yu Hu, Wenhua Liang, Chunquan Ou, Jianxing He, et al. Clinical characteristics of 2019 novel coronavirus infection in China. medRxiv 2020. doi: https://doi.org/10.1101/2020.02.06.20020974.

[9] Chen L, Liu HG, Liu W, Liu J, Liu K, Shang J, et al. Analysis of clinical features of 29 patients with 2019 novel coronavirus pneumonia. Zhonghua Jie He He Hu Xi Za Zhi 2020.43(0):E005.

[10] Kaiyuan Sun, Jenny Chen, Cecile Viboud. Early epidemiological analysis of the 2019-nCoV outbreak based on a crowdsourced data. medRxiv 2020. doi: https://doi.org/10.1101/2020.01.31.20019935.

[11] Yang Yang, Qingbin Lu, Mingjin Liu, Yixing Wang, Anran Zhang, Neda Jalali, et al. Epidemiological and clinical features of the 2019 novel coronavirus outbreak in China. medRxiv 2020. doi: https://doi.org/10.1101/2020.02.10.20021675.

[12] Jie Li, Shilin Li, Yurui Cai, Qin Liu, Xue Li, Zhaoping Zeng, et al. Epidemiological and Clinical Characteristics of 17 Hospitalized Patients with 2019 Novel Coronavirus Infections Outside Wuhan, China. medRxiv 2020. doi: https://doi.org/10.1101/2020.02.11.20022053.

[13] The Noval Coronavirus Pneumonia Emergency Response Epidemiology Team, Chinese Center for Disease Control and Prevention. The epidemiological

medRxiv preprint doi: https://doi.org/10.1101/2020.02.18.20024539; this version posted February 23, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.

characteristics of an outbreak of 2019 novel coronavirus diseases (COVID-19) in China. Zhong Hua Liu Xing Bing Xue Za Zhi 2020. 41(2):145-151.

[14] Ji W, Wang W, Zhao X, Zai J, Li X. Homologous recombination within the spike glycoprotein of the newly identified coronavirus may boost cross-species transmission from snake to human. J Med Virol 2020. doi: 10.1002/jmv.25682.

[15] Benvenuto D, Giovannetti M, Ciccozzi A, Spoto S, Angeletti S, Ciccozzi M. The 2019-new coronavirus epidemic: evidence for virus evolution. J Med Virol 2020. doi: 10.1002/jmv.25688.

[16] Zhou P, Yang XL, Wang XG, Hu B, Zhang L, Zhang W, et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature 2020. doi:https://doi.org/10.1038/s41586-020-2012-7.

[17] Wu F, Zhao S, Yu B, Chen YM, Wang W, Song ZG, et al. A new coronavirus associated with human respiratory disease in China. Nature 2020. doi:https://doi.org/10.1038/s41586-020-2008-3.

[18] Hui DSC, Zumla A. Severe Acute Respiratory Syndrome: Historical, Epidemiologic, and Clinical Features. Infect Dis Clin North Am 2019. 33(4):869-889.

[19] Azhar EI, Hui DSC, Memish ZA, Drosten C, Zumla A. The Middle East Respiratory Syndrome (MERS). Infect Dis Clin North Am 2019. 33(4):891-905.

[20] Sheng G, Chen P, Wei Y, Yue H, Chu J, Zhao J, et al. Viral Infection Increases the Risk of Idiopathic Pulmonary Fibrosis: A Meta-Analysis. Chest 2019. doi: 10.1016/j.chest.2019.10.032.

medRxiv preprint doi: https://doi.org/10.1101/2020.02.18.20024539; this version posted February 23, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.

[21] Xie L, Liu Y, Xiao Y, et al, 2005. Follow-up study on pulmonary function and lung radiographic changes in rehabilitating severe acute respiratory syndrome patients after discharge. Chest. 127(6):2119-24.

[22] Hui DS, Joynt GM, Wong KT, et al, 2005. Impact of severe acute respiratory syndrome (SARS) on pulmonary function, functional capacity and quality of life in a cohort of survivors. Thorax. 60(5):401-9.

[23] Yu Zhao, Zixian Zhao, Yujia Wang, et al, 2020.Single-cell RNA expression profiling of ACE2, the putative receptor of Wuhan 2019-nCov. bioRxiv.doi: https://doi.org/10.1101/2020.01.26.919985.

[24] Holshue ML, DeBolt C, Lindquist S, et al, 2020. First Case of 2019 Novel Coronavirus in the United States. N Engl J Med.doi: 10.1056/NEJMoa2001191.

[25] Buret AG, 2010. Immuno-modulation and anti-inflammatory benefits of antibiotics: the example of tilmicosin. Can J Vet Res. 74(1):1-10.

[26] Wuyts WA, Willems S, Vos R, et al, 2010. Azithromycin reduces pulmonary fibrosis in a bleomycin mouse model. Exp Lung Res. 36(10):602-14.

[27] Luo F, Zhuang Y, Sides MD, et al, 2014. Arsenic trioxide inhibits transforming growth factor-β1-induced fibroblast to myofibroblast differentiation in vitro and bleomycin induced lung fibrosis in vivo. Respir Res. 15:51.

[28] Wang Chunbin，Zhang Shuang，Zhang Qian, et al, 2019. Research Progress of Two New Antifibrotic Drugs for Idiopathic Pulmonary Fibrosis. Chin Pharm J. 09:682-686.

medRxiv preprint doi: https://doi.org/10.1101/2020.02.18.20024539; this version posted February 23, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.

Figure legends

Figure 1. PRISMA flow diagram

Figure 2. Meta-analysis of the incidence of fever

Figure 3. Meta-analysis of the incidence of cough

Figure 4. Meta-analysis of the incidence of muscle soreness or fatigue

Figure 5. Meta-analysis of the incidence of ARDS

Figure 6. Meta-analysis of the incidence of abnormal chest CT

Figure 7. Meta-analysis of the proportion of severe cases in all infected cases

Figure 8. Meta-analysis of the mortality rate of patients with 2019-nCoV infection

medRxiv preprint doi: https://doi.org/10.1101/2020.02.18.20024539; this version posted February 23, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

Table 1:The characteristics of the literature

First Author	Year	Country	Follow-up (days)	No. Patients	Sex	Average Age	Research Type	Literature Quality	Clinlcal Symptom
Chaolin Huang[5]	2020	China	18	41	Male:30 Female:11	49	Retrospective Study	7	Fever ARDS Muscle Soreness or Fatigue Cough Abnormal Chest CT Patient in Critical Condition Death of Patient
Dawei Wang[6]	2020	China	34	138	Male:75 Female:63	56	Retrospective Study	7	Fever ARDS Muscle Soreness or Fatigue Cough Abnormal Chest CT Patient in Critical Condition Death of Patient
Nanshan Chen[7]	2020	China	25	99	Male:67 Female:32	55.5	Retrospective Study	6	Fever ARDS Muscle Soreness or Fatigue Cough Abnormal Chest CT Death of Patient

medRxiv preprint doi: https://doi.org/10.1101/2020.02.18.20024539; this version posted February 23, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

Weijie Guan[8]	2020	China	28	1099	Male:640 Female:459	47	Retrospective Study	8	Fever ARDS Muscle Soreness or Fatigue Cough Abnormal Chest CT Patient in Critical Condition Death of Patient
Lei Chen[9]	2020	China	15	29	Male:21 Female:8	56	Retrospective Study	6	Fever Muscle Soreness or Fatigue Cough Patient in Critical Condition Death of Patient
Kaiyuan Sun[10]	2020	America	42	288	Male:182 Female:106	44	Retrospective Study	5	Death of Patient
Yang Yang[11]	2020	China	51	4021	Male:2211 Female:1810	49	Retrospective Study	5	Patient in Critical Condition Death of Patient
Jie Li[12]	2020	China	21	17	Male:9 Female:8	45	Retrospective Study	6	Fever Muscle Soreness or Fatigue Cough Abnormal Chest CT
China CDC[13]	2020	China	43	44672	Male:22981 Female:21691	--	Retrospective Study	6	Patient in Critical Condition Death of Patient

China CDC: Chinese Center for Disease Control and Prevention.

medRxiv preprint doi: https://doi.org/10.1101/2020.02.18.20024539; this version posted February 23, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

Table 2:Meta-analysis results

Clinlcal Symptom	Results of Meta-analysis	Adjusted Results
Fever	2.53(2.30,2.75)	0.909(0.833,0.962)
ARDS	0.79(0.43,1.15)	0.148(0.046,0.296)
Muscle Soreness or Fatigue	1.39(0.88,1.89)	0.410(0.181,0.657)
Cough	2.00(1.85,2.15)	0.708(0.638,0.774)
Abnormal Chest CT	2.72(2.49,2.95)	0.956(0.898,0.991)

medRxiv preprint doi: https://doi.org/10.1101/2020.02.18.20024539; this version posted February 23, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

Patient in Critical Condition	0.96(0.80,1.11)	0.213(0.152,0.278)
Death of Patient	0.44(0.35,0.52)	0.048(0.03,0.066)

Table 3: Results of Egger test

Clinlcal Symptom	Fever	ARDS	Muscle Soreness or Fatigue	Cough	Abnormal Chest CT	Patient in Critical Condition	Death of Patient
P 值	0.633	0.008	0.168	0.459	0.881	0.978	0.194

medRxiv preprint doi: https://doi.org/10.1101/2020.02.18.20024539; this version posted February 23, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

medRxiv preprint doi: https://doi.org/10.1101/2020.02.18.20024539; this version posted February 23, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .




Study
ID
ES (95% CI)
%
Weight
Chaolin Huang
2.77 (2.46, 3.07)
15.49
Dawei Wang
2.87 (2.71, 3.04)
19.40
Nanshan Chen
2.28 (2.08, 2.47)
18.60
Weijie Guan
2.43 (2.37, 2.49)
21.44
Lei Chen
2.70 (2.34, 3.05)
13.88
Jie Li
1.97 (1.51, 2.43)
11.18
Overall (I-squared = 86.8%, p = 0.000)
2.53 (2.30, 2.75)
100.00
NOTE: Weights are from random effects analysis
-3.07
0
3.07


Study
ID
ES (95% CI)
%
Weight
Chaolin Huang
2.09 (1.79, 2.40)
13.15
Dawei Wang
1.76 (1.59, 1.93)
21.32
Nanshan Chen
2.25 (2.06, 2.45)
19.29
Weijie Guan
1.93 (1.87, 1.99)
27.86
Lei Chen
2.02 (1.66, 2.38)
10.78
Jie Li
2.10 (1.63, 2.56)
7.59
Overall (I-squared = 68.7%, p = 0.007)
2.00 (1.85, 2.15)
100.00
NOTE: Weights are from random effects analysis
-2.56
0
2.56


Study
ID
ES (95% CI)
%
Weight
Chaolin Huang
1.45 (1.15, 1.75)
16.55
Dawei Wang
1.97 (1.80, 2.14)
17.26
Nanshan Chen
0.69 (0.50, 0.89)
17.13
Weijie Guan
0.79 (0.73, 0.85)
17.54
Lei Chen
1.40 (1.05, 1.76)
16.17
Jie Li
2.10 (1.63, 2.56)
15.35
Overall (I-squared = 97.7%, p = 0.000)
1.39 (0.88, 1.89)
100.00
NOTE: Weights are from random effects analysis
-2.56
0
2.56


Study
ID
ES (95% CI)
%
Weight
Chaolin Huang
1.15 (0.85, 1.46)
22.69
Dawei Wang
0.83 (0.66, 0.99)
25.52
Nanshan Chen
0.86 (0.67, 1.06)
25.00
Weijie Guan
0.37 (0.31, 0.43)
26.79
Overall (I-squared = 95.3%, p = 0.000)
0.79 (0.43, 1.15)
100.00
NOTE: Weights are from random effects analysis
-1.46
0
1.46


Study
ID
ES (95% CI)
%
Weight
Chaolin Huang
2.99 (2.68, 3.29)
17.72
Dawei Wang
3.06 (2.89, 3.22)
22.71
Nanshan Chen
2.48 (2.29, 2.68)
21.68
Weijie Guan
2.74 (2.68, 2.80)
25.41
Jie Li
2.10 (1.63, 2.56)
12.48
Overall (I-squared = 86.9%, p = 0.000)
2.72 (2.49, 2.95)
100.00
NOTE: Weights are from random effects analysis
-3.29
0
3.29


Study
ID
ES (95% CI)
%
Weight
Chaolin Huang
1.21 (0.90, 1.51)
11.48
Dawei Wang
1.08 (0.91, 1.24)
16.77
Weijie Guan
0.45 (0.39, 0.51)
20.31
Lei Chen
1.54 (1.18, 1.90)
9.72
Yang Yang
1.01 (0.98, 1.04)
20.78
China CDC
0.89 (0.88, 0.90)
20.94
Overall (I-squared = 98.3%, p = 0.000)
0.96 (0.80, 1.11)
100.00
NOTE: Weights are from random effects analysis
-1.9
0
1.9


Study
ID
ES (95% CI)
%
Weight
Chaolin Huang
0.81 (0.51, 1.11)
5.60
Dawei Wang
0.44 (0.27, 0.60)
11.07
Nanshan Chen
0.69 (0.50, 0.89)
9.50
Weijie Guan
0.24 (0.18, 0.30)
17.52
Lei Chen
0.58 (0.23, 0.94)
4.37
Yang Yang
0.24 (0.21, 0.27)
18.67
Kaiyuan Sun
0.76 (0.64, 0.87)
14.17
China CDC
0.30 (0.29, 0.31)
19.10
Overall (I-squared = 93.6%, p = 0.000)
0.44 (0.35, 0.52)
100.00
NOTE: Weights are from random effects analysis
-1.11
0
1.11